The re-invigoration of impaired anti-tumor immunity is a promising therapeutic approach for cancer treatment. Immune checkpoint blockades such as anti-CTLA-4 and anti-PD-1 antibodies have achieved revolutionary progress in prolonging the survival of patients with advanced melanomas, whereas low response rate and treatment resistance significantly hinder their efficacy. Therefore, it is of necessity to further elucidate the mechanism underlying dampened anti-tumor immunity, so that more potential targets can be discovered. The dysregulation of cell metabolism in tumor microenvironment is the hallmark characteristic of cancer pathogenesis. More importantly, disordered cell metabolism is frequently related to the alteration of various types of protein modifications, including acetylation, lactylation and palmitoylation. Previous studies have mainly emphasized the effect of cell metabolism and related protein modification on the malignant behavior of tumor cell itself, which provides multiple promising druggable targets to restrain cancer progression. However, their role in anti-tumor immunity in melanoma remains elusive.
The goal of this Research Topic is to provide a forum to advance research on the contribution of cell metabolism and related protein modification to the anti-tumor immunity of melanoma as well as to explore the mechanism underlying resistance to current available immunotherapy in the attempt to discover more promising therapeutic targets.
We welcome submissions of Original Research and Review on the sub-topics below:
1) The role of dysregulated tumor cell metabolism in the regulation of infiltrating lymphocytes in tumor microenvironment;
2) Cell metabolism in immune cells and implication in anti-tumor immunity;
3) Post-translational modification proteomics of tumor cell and immune cells in tumor microenvironment;
4) Targeting metabolic enzymes increases the efficacy of melanoma immunotherapy;
5) The connection between cell metabolism and dysregulated protein modification in anti-tumor immunity;
6) Histone modification in regulating the function of immune cells and tumor immune evasion;
7) Metabolomics of tumors and peripheral blood, and their involvement in anti-tumor immunity and response to immunotherapy in melanoma.
The re-invigoration of impaired anti-tumor immunity is a promising therapeutic approach for cancer treatment. Immune checkpoint blockades such as anti-CTLA-4 and anti-PD-1 antibodies have achieved revolutionary progress in prolonging the survival of patients with advanced melanomas, whereas low response rate and treatment resistance significantly hinder their efficacy. Therefore, it is of necessity to further elucidate the mechanism underlying dampened anti-tumor immunity, so that more potential targets can be discovered. The dysregulation of cell metabolism in tumor microenvironment is the hallmark characteristic of cancer pathogenesis. More importantly, disordered cell metabolism is frequently related to the alteration of various types of protein modifications, including acetylation, lactylation and palmitoylation. Previous studies have mainly emphasized the effect of cell metabolism and related protein modification on the malignant behavior of tumor cell itself, which provides multiple promising druggable targets to restrain cancer progression. However, their role in anti-tumor immunity in melanoma remains elusive.
The goal of this Research Topic is to provide a forum to advance research on the contribution of cell metabolism and related protein modification to the anti-tumor immunity of melanoma as well as to explore the mechanism underlying resistance to current available immunotherapy in the attempt to discover more promising therapeutic targets.
We welcome submissions of Original Research and Review on the sub-topics below:
1) The role of dysregulated tumor cell metabolism in the regulation of infiltrating lymphocytes in tumor microenvironment;
2) Cell metabolism in immune cells and implication in anti-tumor immunity;
3) Post-translational modification proteomics of tumor cell and immune cells in tumor microenvironment;
4) Targeting metabolic enzymes increases the efficacy of melanoma immunotherapy;
5) The connection between cell metabolism and dysregulated protein modification in anti-tumor immunity;
6) Histone modification in regulating the function of immune cells and tumor immune evasion;
7) Metabolomics of tumors and peripheral blood, and their involvement in anti-tumor immunity and response to immunotherapy in melanoma.